EACH: A randomised phase II study evaluating the safety and anti-tumour activity of the combination of avelumab and cetuximab relative to avelumab monotherapy in recurrent/metastatic head and neck squamous cell cancer.

Authors

Martin David Forster

University College London Hospitals, London, United Kingdom

Martin David Forster , Joseph J. Sacco , Anthony Hee Kong , Graham Wheeler , Sharon Forsyth , Reshma Bhat , Kameka Blair , Helen Lowe , Victoria J Spanswick , Leah Ensell , John A. Hartley , Laura White

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Nanoparticle albumin-bound (nab) paclitaxel in combination with nivolumab as treatment of recurrent or metastatic head and neck squamous-cell carcinoma (RM-HNSCC) that progressed on a PD-1 inhibitor: A single-arm, phase 2 trial.

First Author: Jared Cohen

insert_chart_outlined

Poster

2015 ASCO Annual Meeting

bookmark_border

KEYNOTE-055: A phase II trial of single agent pembrolizumab in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who have failed platinum and cetuximab.

First Author: Steven Francis Powell

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.

First Author: Douglas Adkins

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.

First Author: Benjamin Philip Levy